RHHBY - As CRISPR continues to falter other CAR-T names aren't impacted

Although shares of CRISPR Therapeutics (CRSP -6.4%) have fallen since yesterday's after-the-bell announcement, its gene editing peers have not been impacted. Those results were from the company’s early-stage trial of its CAR-T cell therapy CTX110. Autolus Therapeutics (AUTL +5.8%) is on the rise. The company is developing T cell therapies for cancer. Allogene Therapeutics (ALLO +8.1%), which suffered its own woes last week following a clinical hold on trials, is up. Caribou BioSciences (CRBU +1.9%), which is developing genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors, is also seeing gains. Adaptimmune Therapeutics (ADAP +4.4%) is working on cell therapies for solid tumors. Last month, it reached a deal with Roche (OTCQX:RHHBY +0.3%) unit Genentech to develop allogenic gene therapies. Sorrento Therapeutics (SRNE +1.9%) has a CD38 CAR-T therapy in phase 1 for multiple myeloma. Earlier today, the company said the FDA approved clinical trials for its antibody

For further details see:

As CRISPR continues to falter, other CAR-T names aren't impacted